Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

Authors

  • Andrea Cortese Dermatology, Humanitas Research Hospital – IRCCS, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Saverio Pancetti Pathology, Humanitas Research Hospital - IRCCS, Rozzano (MI), Italy
  • Tiziana Pressiani Oncology, Humanitas Research Hospital - IRCCS, Rozzano (MI), Italy
  • Francesco Toso Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Giovanni Fiorillo Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Costanzo Antonio Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
  • Riccardo G. Borroni Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy

Keywords:

sorafenib, acute generalized exanthematous pustulosis, severe cutaneous adverse reaction, tyrosin-kinase inhibitors

References

Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-119. DOI: 10.1034/j.1600-0560.2001.028003113.x. PMID: 11168761.

Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-996. DOI: 10.1111/j.1365-2133.2007.08156.x. PMID: 17854366.

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. DOI: 10.1038/clpt.1981.154. PMID: 7249508.

Bracarda S, Ruggeri EM, Monti M, et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol. 2012;82(3):378-386. DOI: 10.1016/j.critrevonc.2011.08.005. PMID: 21944842.

Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443-445. DOI: 10.1111/j.1365-2133.2011.10377.x. PMID: 21495998.

Pretel M, Iñarrairaegui M, Lera JM, Aguado L, Idoate MA. Acute generalized exanthematous pustulosis induced by sorafenib. JAMA Dermatol. 2014;150(6):664-666. DOI: 10.1001/jamadermatol.2013.6924. PMID: 24671701.

Alegre-Sánchez A, de Perosanz-Lobo D, Pinilla-Pagnon I, Muñoz-Zato E. Sorafenib-induced Acute Generalized Exanthematous Pustulosis: An Increasing Association? Actas Dermosifiliogr. 2017;108(6):599-601. DOI: 10.1016/j.ad.2016.11.018. PMID: 28262110.

Downloads

Published

2023-04-29

How to Cite

1.
Cortese A, Pancetti S, Pressiani T, et al. Sorafenib-Induced Acute Generalized Exanthematous Pustulosis. Dermatol Pract Concept. 2023;13(2):e2023130. doi:10.5826/dpc.1302a130

Share